Floatz logo

Satraplatin

Carcinoma, Non-small Cell Lung

AgennixSmall moleculePhase 2Dormant
CCC
55/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
40/ 100
Competitive Position
89/ 100

Competitive context

1206 Active assets in the Carcinoma, Non-small Cell Lung cohort.

Asset / SponsorPhaseRating
Necitumumab
Jonsson Comprehensive Cancer Center
Phase 3BBB
Zorifertinib
Alpha Biopharma (Jiangsu) Co., Ltd.
Phase 2/3BBB
Glumetinib
Shanghai JMT-Bio Inc.
Phase 3BBB
d-0316
Betta Pharmaceuticals Co., Ltd.
Phase 2/3BBB
Onartuzumab
Hoffmann-La Roche
Phase 3BBB

View all 50 →

Same molecule, other indications

Satraplatin is also rated in:

Hormone Refractory Prostate CancerDormant
CCC
Indicative ·
55 / 100
View asset →
prostate cancerDormant
CCC
Indicative ·
54 / 100
View asset →
disease of genetic or genomic mechanismDormant
CCC
Indicative ·
50 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →